Wayne State University School of Medicine, Detroit, MI, USA.
Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Adv Exp Med Biol. 2021;1311:89-101. doi: 10.1007/978-3-030-65768-0_6.
Despite advances in screening, therapy, and surveillance that have improved patient survival rates, breast cancer is still the most commonly diagnosed cancer and the second leading cause of cancer mortality among women [1]. Breast cancer is a highly heterogeneous disease rooted in a genetic basis, influenced by extrinsic stimuli, and reflected in clinical behavior. The diversity of breast cancer hormone receptor status and the expression of surface molecules have guided therapy decisions for decades; however, subtype-specific treatment often yields diverse responses due to varying tumor evolution and malignant potential. Although the mechanisms behind breast cancer heterogeneity is not well understood, available evidence suggests that studying breast cancer metabolism has the potential to provide valuable insights into the causes of these variations as well as viable targets for intervention.
尽管在筛查、治疗和监测方面取得了进展，提高了患者的生存率，但乳腺癌仍然是最常见的癌症，也是女性癌症死亡的第二大原因[1]。乳腺癌是一种高度异质性的疾病，其根源在于遗传基础，受外在刺激影响，并反映在临床行为上。几十年来，乳腺癌激素受体状态和表面分子表达的多样性一直指导着治疗决策；然而，由于肿瘤的不断进化和恶性潜能的不同，亚型特异性治疗往往会产生不同的反应。尽管乳腺癌异质性的机制尚不清楚，但现有证据表明，研究乳腺癌代谢有可能为这些变化的原因以及可行的干预靶点提供有价值的见解。
